Progress of pharmacokinetic characteristics of adefovir dipivoxil

Chinese Pharmaceutical Journal

Volumn 40, Issue 1, 2005, Pages 6-10

  Jiang, Ye ^a   Xu, Zhi Ru ^a   Zhang, Xiao Qing ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG EFFECT; DRUG FORMULATION; DRUG SCREENING; VIRUS INFECTION;

EID: 14744280452     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Starrett JE Jr, Tortolani DR, Russell J, et al. Synthesis, oral bioavailability determination, in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonylmethoxy) ethyl] adenine (PMEA) [J]. J Med Chem, 1994, 37(12):1857.
2. Yokota T, Mochizuki S, Konno K, et al. Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis[J]. Antimicrob Agents Chemother, 1991, 35(2):394.
3. Heijtink RA, Wilde GAD, Kruining J, et al. Inhibitory effect of 9-(2-phosphonyl methoxyethyl) adenine (PMEA) on human and duck hepatitis B virus infection[J]. Antiviral Res, 1993, 21:141.
4. de Clercq E. Therapeutic potential of phosphonyhnethoxyalkylpurines and pyrimidines as antiviral agents[J]. Drugs Exp Clin Res, 1990, 16 (7):319.
5. Delmas J, Schorr O, Jamard C, et al. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro [J]. Antimicrob Agents Chemother, 2002, 46(2):425.
6. Palu G, Stefanelli S, Rassu M, et al. Celluer uptake of phosphonylmethoxyalkyl purine derivatives[J]. Antiviral Res, 1991, 16(1):115.
7. Cundy KC, Barditch-Crovo P, Walker R, et al. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type-1 infected patients[J]. Antimicrob Agents Chemother, 1995, 39(11):2401.
8. Stuart N, Karen LG. Adefovir dipivoxil[J]. Drugs, 1999, 58(3): 479.
9. Balzarini J, Hao Z, Herdewijn P, et al. Intracelluar metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonyhnethoxyethyl) adenine, a potent anti-HIV compound[J]. Proc Natl Acad Sci, 1991, 88(4):1499.
10. Cundy KC, Fishback JA , Shaw PC, et al. Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl) adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys [J]. Pharm Res, 1994, 11(6): 839.
11. Shaw JP, Louie MS, Krishnamurthy VV, et al. Pharmacokinetics and metabolism of selected prodrug of PMEA in rats[J]. Drug Metab Dapos, 1997, 25(3):362.
12. Naesens L, Balzarini J, Bischofberger N, et al. Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2- phosphonylmethoxy-ethyl) adenine, the bis (pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxy-ethyl) adenine[J]. Antimicrob Agents Chemother, 1996, 40(1):22.
13. Cullen JM, Daniel HL, Brown C, et al. Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-inficted woodchucks[J]. Am Soc Microbiol ,2001, 45(10): 2740.
14. Cundy KC, Sue IL, Visor GC, et al. Oral formulations of adefovir dipivoxil: in vitro dislution and in vivo bioaviailability in dogs[J]. J Pharm Sci, 1997, 86(12):1334.
15. Gilead Science Inc. Hepsera™ (adefovir dipivoxil) Full Prescribing Information [EB/OL]. http://www.gilead.com, 2002-09-02.
16. Naesens L, Balzarini J, Clercq ED. Pharmacokinetics in mice of the anti-retrovirus agent 9-(2-phosphonylmethoxyethyl)adenine[J]. Drug Metab Dispos, 1992, 20(5):747.
17. Biessen EAL, Valentijn ARPM, Vrueh RLADE, et al. Novel hepatotiophic prodrugs of the antiviral nuleoside 9-(2-phosphonyl-methoxyethyl) adenine with improved pharmacokinetics and antiviral activity[J]. FASEB J, 2000, 14(12):1784.
18. Baiditch CP, Toole J, Hendrix CW, et al. Anti-Human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil 9-(2-(bispivaloyl-oxymethyl) phosphonomethoxy) ethyl] adenine in HIV-infected patients [J]. J Infec Dis, 1997, 176(2):406.
19. Hughes WT, Shenep JL, Rodman JH, et al. Single-dose pharmacokinetics and safety of the oral antivrial compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1[J]. Antimicrob Agents Chemother, 2000, 44(4):1041.